Genetic and Epigenetic Biomarkers For Diagnosis, Prognosis and Treatment Of Metabolic Syndrome

CONCLUSION: For the screening, diagnosis, and prognosis of metabolic syndrome and the prescription of personalized medicine, the DNA methylation biomarkers specify for subjects have been recognized as an ensuring tool. While these results are promising, further investigations are needed to unravel the complicated synergic association of the genome, epigenome and the situations related to metabolic pathology.PMID:33845722 | DOI:10.2174/1381612827666210412145915

Source: Current Pharmaceutical Design - April 13, 2021 Category: Drugs & Pharmacology Authors: Rosaria V Giglio Anca P Stoian Angelo M Patti Ali A Rizvi Vasily Sukhorukov Marcello Ciaccio Alexander Orekhov Manfredi Rizzo Source Type: research